S2632 |
BMS-378806
|
BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus. |
-
Commun Biol, 2023, 6(1):535
-
J Virol, 2021, 95(24):e0052921
-
J Virol, 2020, 10.1128/JVI.00148-20
|
|
S8960 |
CD38 inhibitor 1 (compound 78c)
|
CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively. |
-
Cell Rep Med, 2024, 5(2):101400
-
Cell Rep Med, 2023, S2666-3791(23)00310-5
-
Cell Rep Med, 2023, 4(9):101157
|
|
S5525 |
SodiuM Metatungstate
|
Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively. |
-
Immunology, 2022, 10.1111/imm.13493
-
Cancer Cell, 2021, 39(7):973-988.e9
|
|
S6239 |
PMX-53
|
PMX-53 is a potent CD88 (C5aR) antagonist and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50 values of 22 nM and 75 nM, respectively. PMX-53 is also an agonist of Mas-related gene 2 (MrgX2). |
-
Thromb J, 2022, 20(1):24
|
|
S0141 |
NQ301
|
NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets. |
-
J Extracell Vesicles, 2021, 10(5):e12078
|
|
S9867 |
LY-3475070
|
LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase). |
-
Theranostics, 2024, 14(3):1224-1240
-
Immunology, 2022, 10.1111/imm.13493
|
|
S0474 |
Avacopan
|
Avacopan is an orally administered and selective C5a receptor (C5aR) antagonist. |
-
Cell Death Dis, 2022, 13(5):500
|
|
S3301 |
Cynarin
|
Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization. |
|
|
S0525 |
ADH-503 (GB1275)
|
ADH-503 (GB1275, (Z)-Leukadherin-1 choline) is the salt form of leukadherin-1 and acts as a potent allosteric agonist of CD11b. |
|
|
A2127New |
Anti-human CD28-InVivo
|
Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro. |
|
|
S8908 |
AB680
|
AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73. |
|
|
A2039 |
Isatuximab (anti-CD38)
|
Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM. |
|
|
E1276 |
MK-0159
|
MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart. |
|
|
S7487 |
YYA-021
|
YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4. |
|
|
E1305New |
RBN013209
|
RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer. |
|
|
A2125New |
Anti-mouse OX40 (CD134)-InVivo
|
Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo. |
|
|
A2034 |
Elotuzumab (anti-SLAMF7)
|
Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity. |
-
Nat Commun, 2024, 15(1):1367
|
|
D4005New |
Vorsetuzumab mafodotin
|
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma. |
|
|
S6347 |
5'-N-Ethylcarboxamidoadenosine (NECA)
|
5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway. |
|
|
D4012New |
Polatuzumab vedotin-piiq
|
Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). |
|
|
D4016New |
Iladatuzumab vedotin
|
Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. |
|
|
D4017New |
Pinatuzumab vedotin
|
Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. |
|
|
S6727 |
AX-024 HCl
|
AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. |
|
|
D4030New |
Vadastuximab talirine
|
Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients. |
|
|
D4034New |
Lorvotuzumab mertansine
|
Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). |
|
|
D4039New |
Praluzatamab ravtansine
|
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. |
|
|
D4045New |
Brentuximab vedotin
|
Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma. |
|
|
A3175New |
Blinatumomab (Anti-CD3 & CD19)
|
Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts. |
|
|
D4051New |
Tisotumab vedotin
|
Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer. |
|
|
D4055New |
Loncastuximab tesirine
|
Loncastuximab tesirine (ADCT-402, RB4v1.2-SG-3249) is an antibody-drug conjugate (ADC) composed of an anti-CD19 (B lymphocyte surface antigen B4, Leu-12) chimeric monoclonal antibody , conjugated to Pyrrolobenzodiazepine (PDB) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG. |
|
|
A2127New |
Anti-human CD28-InVivo
|
Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro. |
|
|
A2039 |
Isatuximab (anti-CD38)
|
Isatuximab (anti-CD38) (SAR650984, hu38SB19) is an IgG1-derived monoclonal antibody that binds to a specific extracellular epitope of CD38 receptor with a kd of 0.12 nM. |
|
|
A2125New |
Anti-mouse OX40 (CD134)-InVivo
|
Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo. |
|
|
A2034 |
Elotuzumab (anti-SLAMF7)
|
Elotuzumab (anti-SLAMF7, BMS-901608, PDL063, HuLuc63) is a humanized monoclonal antibody that binds human signaling lymphocytic activation molecule F7 (hSLAMF7, also known as CS1, CD319, or CRACC). Elotuzumab shows a dual mechanism of action that includes the direct activation of natural killer (NK) cells and the induction of NK cell–mediated antibody-dependent cellular cytotoxicity. |
- Nat Commun, 2024, 15(1):1367
|
|
A3175New |
Blinatumomab (Anti-CD3 & CD19)
|
Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts. |
|
|
S2632 |
BMS-378806
|
BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus. |
- Commun Biol, 2023, 6(1):535
- J Virol, 2021, 95(24):e0052921
- J Virol, 2020, 10.1128/JVI.00148-20
|
|
S8960 |
CD38 inhibitor 1 (compound 78c)
|
CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively. |
- Cell Rep Med, 2024, 5(2):101400
- Cell Rep Med, 2023, S2666-3791(23)00310-5
- Cell Rep Med, 2023, 4(9):101157
|
|
S5525 |
SodiuM Metatungstate
|
Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively. |
- Immunology, 2022, 10.1111/imm.13493
- Cancer Cell, 2021, 39(7):973-988.e9
|
|
S0141 |
NQ301
|
NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. NQ301 inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets. |
- J Extracell Vesicles, 2021, 10(5):e12078
|
|
S9867 |
LY-3475070
|
LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase). |
- Theranostics, 2024, 14(3):1224-1240
- Immunology, 2022, 10.1111/imm.13493
|
|
S3301 |
Cynarin
|
Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. Cynarin blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization. |
|
|
S8908 |
AB680
|
AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73. |
|
|
E1276 |
MK-0159
|
MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart. |
|
|
S7487 |
YYA-021
|
YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4. |
|
|
E1305New |
RBN013209
|
RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer. |
|
|
D4005New |
Vorsetuzumab mafodotin
|
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma. |
|
|
S6347 |
5'-N-Ethylcarboxamidoadenosine (NECA)
|
5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. 5'-N-Ethylcarboxamidoadenosine acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway. |
|
|
D4012New |
Polatuzumab vedotin-piiq
|
Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). |
|
|
D4016New |
Iladatuzumab vedotin
|
Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. |
|
|
D4017New |
Pinatuzumab vedotin
|
Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. |
|
|
S6727 |
AX-024 HCl
|
AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). AX-024 HCl also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. |
|
|
D4030New |
Vadastuximab talirine
|
Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients. |
|
|
D4034New |
Lorvotuzumab mertansine
|
Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). |
|
|
D4039New |
Praluzatamab ravtansine
|
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. |
|
|
A2127New |
Anti-human CD28-InVivo
|
Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro. |
|
|
E1305New |
RBN013209
|
RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer. |
|
|
A2125New |
Anti-mouse OX40 (CD134)-InVivo
|
Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo. |
|
|
D4005New |
Vorsetuzumab mafodotin
|
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma. |
|
|
D4012New |
Polatuzumab vedotin-piiq
|
Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). |
|
|
D4016New |
Iladatuzumab vedotin
|
Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. |
|
|
D4017New |
Pinatuzumab vedotin
|
Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. |
|
|
D4030New |
Vadastuximab talirine
|
Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients. |
|
|
D4034New |
Lorvotuzumab mertansine
|
Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). |
|
|
D4039New |
Praluzatamab ravtansine
|
Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. |
|
|
D4045New |
Brentuximab vedotin
|
Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma. |
|
|
A3175New |
Blinatumomab (Anti-CD3 & CD19)
|
Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts. |
|
|
D4051New |
Tisotumab vedotin
|
Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer. |
|
|
D4055New |
Loncastuximab tesirine
|
Loncastuximab tesirine (ADCT-402, RB4v1.2-SG-3249) is an antibody-drug conjugate (ADC) composed of an anti-CD19 (B lymphocyte surface antigen B4, Leu-12) chimeric monoclonal antibody , conjugated to Pyrrolobenzodiazepine (PDB) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG. |
|
|